The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

FDA grants Orphan Drug Designation to Reolysin in pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

FDA granted an Orphan Drug Designation to antinuclear antibody conjugated liposomal doxorubicin, developed by NanoSmart Pharmaceuticals Inc., for the treatment of Ewing’s sarcoma, a rare cancer that develops in or around children’s bones.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Health Equity

ACS is using an AI-powered platform in the largest-ever population study of Black women
Time and resources freed up from data management will go to outreach and access

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.
By Jacquelyn Cobb
NCI Trials

NCI Trials for August 2024

The National Cancer Institute approved the following clinical research studies last month.   For further information, contact the principal investigator listed. Phase II - ALTE2321 Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors Children’s Oncology GroupMendoza, Jason A.(206) 884-1261 Phase...

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account